“Strong commercial performance of IBSRELA continues, ending FY 2023 with $80.1M in net product sales revenue; 2024 net product sales revenue currently expected to be between $140M to $150M XPHOZAH launch off to a strong start, ending FY 2023 with $2.5 M in net product sales revenue…”As of December 31, the company had total cash, cash equivalents and short-term investments of $184.3 million, compared to total cash, cash equivalents and short-term investments of $123.9 million as of December 31, 2022. During the quarter ended December 31, 2023, the company drew $22.4 million in net proceeds under its term loan with SLR Investment Corp. Subsequent to December 31, in January 2024, the company received a $3.0 million milestone payment from Fosun Pharma following the U.S. approval of XPHOZAH.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See today’s best-performing stocks on TipRanks >>
Read More on ARDX:
- Ardelyx Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update
- After a Significant Stock Run, Market Awaits Ardelyx’s (NASDAQ:ARDX) Q4 Earnings
- Ardelyx call volume above normal and directionally bullish
- Ardelyx to Report Fourth Quarter and Full Year 2023 Financial Results on February 22, 2024
- Ardelyx put volume heavy and directionally bearish
